Table 1.
Patient baseline characteristics by survivors and non-survivors
| All | Survivors | Non-survivors | p valuei | |
|---|---|---|---|---|
| N = 30,614 (%) | N = 28,912 (%) | N = 1702 (%) | ||
| Gender, male | 22,608 (74) | 21,431 (74) | 1177 (69) | < 0.001 |
| Age, years | 63 (IQR 12) | 63 (IQR 12) | 67 (IQR 9) | < 0.001 |
| STEMIa | 12,995 (42) | 12,370 (43) | 625 (37) | < 0.001 |
| PCIb | 24,416 (80) | 23,292 (81) | 1124 (66) | < 0.001 |
| LVEFc | < 0.001 | |||
| > 50% | 20,394 (67) | 19,529 (68) | 865 (51) | |
| 40–49% | 6176 (20) | 5784 (20) | 392 (23) | |
| 30–39% | 3192 (10) | 2875 (10) | 317 (19) | |
| < 30% | 852 (3) | 724 (3) | 128 (8) | |
| Body mass index (kg/m2) | 27 (IQR 5) | 27 (IQR 5) | 26 (IQR 6) | < 0.001 |
| Physical activity leveld | < 0.001 | |||
| Low | 6434 (21) | 5745 (20) | 689 (41) | |
| Medium | 8815 (29) | 8433 (29) | 382 (22) | |
| High | 15,365 (50) | 14,734 (52) | 631 (37) | |
| Smoking status | < 0.001 | |||
| Never-smokers | 9849 (32) | 9421 (33) | 428 (25) | |
| Former smokerse | 17 183 (56) | 16,243 (56) | 940 (55) | |
| Smokers | 3582 (12) | 3248 (11) | 334 (20) | |
| HQoLf, EQ5D | 0.85 (IQR 0.27) | 0.85 (IQR 0.27) | 0.80 (IQR 0.34) | < 0.001 |
| eGFRg <60 mL/min/1.73 m2 | 28,174 (92) | 26,865 (93) | 1309 (77) | < 0.001 |
| Full pharmacological treatmenth | 21,300 (70) | 20 173 (70) | 1127 (66) | 0.002 |
Data presented as numbers with percentages in brackets or median with IQR in brackets
aST elevation myocardial infarction
bPercutaneous coronary intervention
cLeft ventricular ejection fraction
dPhysical activity level; low = 0–1 sessions/week; medium = 2–4 sessions/week and high = 5–7 sessions/week
eNo smoking during the last month
fHealth-related quality of life
gEstimated glomerular filtration rate
hACE-inhibitors, beta-blocking agent, statins or other lipid-lowering agents and anti-thrombogenic agents
iDifferences between survivors and non-survivors